Loading...
Advances and application of radioimmunotherapy in non-Hodgkin lymphoma
The activity of radio-immuno conjugate in Non-Hodgkin Lymphoma (NHL) has resulted in FDA approval of two antibodies, Y(90) Ibritumomab tiuxetan and I(131) tositumomab. Both these agents target CD20, a receptor widely expressed in B-Cell NHL. These immunoconjugates deliver their radioactive payload t...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
e-Century Publishing Corporation
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3384399/ https://ncbi.nlm.nih.gov/pubmed/22762027 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|